Regeneron Pharmaceuticals Inc (REGN) fair value: what the stock is really worth
As of Nov 4, 2026: fair value (intrinsic value) of Regeneron Pharmaceuticals Inc stock $1,275, price $931, upside +37.0%, quality 74 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
60‑month range $479.88 – $1,191 · fair‑value band $617.24 – $1,923 · the $930.67 price screens below the $1,275 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 5, 2026.
Follow Regeneron Pharmaceuticals in your weekly email
Every Wednesday you see whether Regeneron Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.
Show moreShow less
The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions.
It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis.
It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency.
Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies.
The company was incorporated in 1988 and is based in Tarrytown, New York.
Stock analysis
Regeneron Pharmaceuticals Inc (REGN) currently trades at $930.67, while our model-based Fair Value estimate is $1,275, implying the stock looks roughly 27% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $1,479 per share, and 13 of the 26 models we run sit above the $930.67 price.
Bear case: the Economic Profit group reads lowest at $441.87, and 13 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: $617.24 (bear) to $1,923 (bull), the price of $930.67 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 74/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Regeneron Pharmaceuticals Inc reported revenue of $14.3B in FY2025 versus $16.1B in FY2021, a compound −2.8%/yr. Reported net income was $4.5B in FY2025, compounding −13.6%/yr from FY2021.
Key figures
Market cap $99.4B Large · P/E ratio 22.9 · P/S ratio 6.40 · EPS (TTM) $39.92 · Dividend yield 0.4% · Net margin 27.9% · Return on equity 14.0% · Return on assets (EBIT) 17.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 79 out of 100 (medium confidence).
What moves the price
The share trades about 4% below its 52-week high and 55% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 8% fair-value upside, at 37%, REGN screens cheaper than that median.
Fair Value models
Bear$617.24Fair Value $1,275Bull$1,923
Price $930.67 · Upside +37.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($30.71 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, 9 officers or directors sold shares worth $49.2M and none bought.
SaleHuda Y ZoghbiDirector3× since Feb 19, 2026: 9,877 shares, avg. $925.29$9.1MNov 3, 2026
SaleChristine A PoonDirector7,830 shares at $969.09$7.6MNov 2, 2026
SaleGeorge L SingDirector21,129 shares at $964.38$20.4MNov 2, 2026
SaleJoseph J LarosaEVP General Counsel and Secret4,466 shares at $965.49$4.3MNov 2, 2026
SaleMichael S BrownDirector1,929 shares at $875.00$1.7MOct 30, 202610b5-1 plan
SaleMarion McCourtEVP Commercial2× since Sep 2, 2026: 3,478 shares, avg. $858.73$3.0MOct 30, 202610b5-1 plan
SaleKathryn GuariniDirector3× since Aug 10, 2026: 1,200 shares, avg. $850.00$1.0MOct 30, 202610b5-1 plan
SaleAndrew J MurphyCo-Chief Scientific Officer4,147 shares at $772.70$3.2MOct 14, 202610b5-1 plan
SaleArthur F RyanDirector5× since Feb 9, 2026: 600 shares, avg. $724.47$434,683Jul 2, 202610b5-1 plan
SaleJason PitofskySVP Controller2× since Nov 7, 2025: 2,467 shares, avg. $756.31$1.9MFeb 9, 2026
Plus 1 more entries from the last 12 months.
Plus 14 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.93/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+1.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.0%
Start year 2020 (pandemic). Over 10 years: +13.3% a year
Revenue growth 35 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+6.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+6.3%
Dividend (yield on the price)0.4%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.6.3% vs 22.3%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.42% → 25%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Price in line with expectations
The price assumes less growth than the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+7.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+8.3%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +4.8% a year for the price and +5.7% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (100 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.
AI conclusion: Regeneron's strength lies in record sales from Dupixent, EYLEA HD and Libtayo plus Sanofi alliance expansion that bolsters its immunology platform, yet its main weakness remains thin evidence of a durable moat amid higher R&D commitments.
Main risk: Multiple biosimilars from Amgen, Biocon, Sandoz and others could launch in 2026 and erode prices and margins on the Eylea franchise.
Bull case: Regeneron could use its VelocImmune platform and expanded Sanofi collaboration to accelerate new antibody candidates that offset any Eylea revenue pressure through broader immunology growth.
Bear case: If biosimilar competition intensifies and lawsuits lead to restrictions, Regeneron might see sustained margin compression on key products and slower pipeline progress that limits overall revenue diversification.
Regeneron delivered record sales for Dupixent, EYLEA HD and Libtayo in the latest quarter while expanding its Sanofi alliance to develop four next-generation long-acting antibodies. This strengthens the immunology platform and adds collaboration revenue, yet it also commits the company to higher R&D spending through 2027 amid a crowded pipeline. Will the new programs generate more durable growth than the existing brands alone?
Compare Regeneron Pharmaceuticals Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 559 stocks
Beats the industry median on 9/15 measures
Overall it ranks above its industry peers.
Valuation
Quality Score74 · Top 25%
Fair Value upside+37.0% · Top 25%
Profitability
Return on equity (12 months)14.0% · Top 25%
Return on assets11.1% · Top 25%
Net margin (12 months)27.9% · Top 25%
Operating margin (12 months)33.1% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)16.7% · Above median
Dividend yield (12 months)0.4% · Bottom 25%
Balance sheet
Debt / equity0.06× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Regeneron Pharmaceuticals Inc (REGN) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of $1,275 versus a price of $930.67, about +37% upside (undervalued).
What is the fair value of REGN?
Our model-based fair value for Regeneron Pharmaceuticals Inc is $1,275 (as of Nov 5, 2026), built from audited fundamentals. The current price: $930.67.
What is the quality score of REGN?
Regeneron Pharmaceuticals Inc has a Quality Score of 74/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Regeneron Pharmaceuticals Inc (REGN)?
Our model-based price target is the fair value of $1,275 (as of Nov 5, 2026) from 26 valuation models. Cautious scenario $617.24, optimistic scenario $1,923. It is a calculation from audited fundamentals, not an analyst target.
What is the Regeneron Pharmaceuticals Inc stock forecast for 2026?
Our models put fair value at $1,275, about +37% upside versus a price of $930.67 (undervalued). Cautious scenario $617.24, optimistic scenario $1,923. The calculation is refreshed regularly with new filings.
What is the revenue of Regeneron Pharmaceuticals Inc (REGN)?
Regeneron Pharmaceuticals Inc reported trailing-twelve-month revenue of about $15.5B (latest available figure, as of Nov 5, 2026).
Does Regeneron Pharmaceuticals Inc pay a dividend?
Regeneron Pharmaceuticals Inc currently shows a dividend yield of 0.39% relative to its recent price (as of Nov 5, 2026).
What growth is priced into Regeneron Pharmaceuticals Inc (REGN)?
For today's price to be fair in a discounted-cash-flow model, Regeneron Pharmaceuticals Inc would have to grow free cash flow by +7.3 % per year for five years (discount rate 8.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +11.0 % per year. As of Nov 5, 2026.
What discount rate (WACC) does the fair value of REGN use?
Our models discount Regeneron Pharmaceuticals Inc at 8.1 %: a base by market capitalisation (large), damped by beta 0.15, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Regeneron Pharmaceuticals Inc that is +7.3 % per year a year over ten years, using the same discount rate (8.1 %) and the same formula as our fair value.
How much growth has Regeneron Pharmaceuticals Inc (REGN) delivered so far?
Over the past 5 years revenue at Regeneron Pharmaceuticals Inc grew +11.0 % a year. The price currently implies +7.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Regeneron Pharmaceuticals Inc (REGN) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Regeneron Pharmaceuticals Inc (+7.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Regeneron Pharmaceuticals Inc (REGN)?
The free-cash-flow yield on the price is 4.11 %: that much free cash flow Regeneron Pharmaceuticals Inc produces per unit of market value. When it exceeds the discount rate of our models (8.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Regeneron Pharmaceuticals Inc (REGN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Regeneron Pharmaceuticals Inc it is $1,275 per share (as of Nov 5, 2026), against a price of $930.67. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Regeneron Pharmaceuticals Inc stock overvalued or undervalued in 2026?
As of Nov 5, 2026, REGN trades below its calculated fair value: price $930.67, fair value $1,275, a gap of about +37% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of REGN?
No. The price is what the market pays today ($930.67); the fair value is what the company's own numbers justify ($1,275). For Regeneron Pharmaceuticals Inc the two are $344.35 per share apart. That gap is exactly why we show both numbers side by side.
How much is Regeneron Pharmaceuticals Inc worth?
The market values Regeneron Pharmaceuticals Inc at about $99.4B (market capitalisation, as of Nov 5, 2026). Per share that is $930.67; our models calculate a fair value of $1,275 per share.
What do the bullish and bearish scenarios say about REGN?
Our models span a range for Regeneron Pharmaceuticals Inc: cautious scenario $617.24, base $1,275, optimistic $1,923 per share (as of Nov 5, 2026, price $930.67). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of REGN?
Regeneron Pharmaceuticals Inc trades at a price-to-earnings ratio of 22.9 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $1,275 is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings: 18.7. Other multiples: PEG 1.6, P/B 3.2, P/S 6.4, EV/EBITDA 20.9.
What is the PEG ratio of REGN?
The PEG ratio of Regeneron Pharmaceuticals Inc is 1.58 (P/E divided by earnings growth, as of Nov 5, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Regeneron Pharmaceuticals Inc (REGN)?
Balance-sheet figures for Regeneron Pharmaceuticals Inc (as of Nov 5, 2026): return on equity 14.0%, debt of 0.06 per unit of equity. They feed the Quality Score of 74/100, which measures business quality independently of the share price.
How far is REGN from its 52-week high?
Regeneron Pharmaceuticals Inc trades at $930.67, about 4% below its 52-week high of $973.36 and 55% above the low of $599.96 (as of Nov 4, 2026). Distance from the high says nothing about value: that is what the fair value of $1,275 is for.
Which stocks are comparable to Regeneron Pharmaceuticals Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, argenx SE, Samsung Biologics Co, BeOne Medicines AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Regeneron Pharmaceuticals Inc stock attractive at the current price?
The data as of Nov 5, 2026: price $930.67, calculated fair value $1,275 (+37%), Quality Score 74/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of REGN calculated?
We run Regeneron Pharmaceuticals Inc through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $1,275, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.5% above its aggregate fair value. Regeneron Pharmaceuticals Inc currently trades 27% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Regeneron Pharmaceuticals Inc (REGN)?
The closing price on Nov 4, 2026 was $930.67. Our model-based fair value is $1,275, about +37% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Regeneron Pharmaceuticals Inc right now?
The model range is unusually wide ($617.24 to $1,923). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid quality (74/100) at a price below fair value, the discount is the argument here, not the business quality.
Where does the earnings growth of Regeneron Pharmaceuticals Inc (REGN) come from?
Earnings per share at Regeneron Pharmaceuticals Inc grew +24.1 % a year from 2014 to 2025. Broken into its drivers: revenue per share +15.3 %, EBIT margin −0.4 %, tax rate +5.4 %, residual (interest, one-offs) +2.6 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Regeneron Pharmaceuticals Inc
How large is the market capitalisation of Regeneron Pharmaceuticals Inc (REGN)?
The market capitalisation of Regeneron Pharmaceuticals Inc is $99.4B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Regeneron Pharmaceuticals Inc (REGN)?
The price-to-sales ratio of Regeneron Pharmaceuticals Inc is 6.40 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Regeneron Pharmaceuticals Inc (REGN)?
Earnings per share at Regeneron Pharmaceuticals Inc are $39.92 (price ÷ EPS = P/E 22.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Regeneron Pharmaceuticals Inc (REGN)?
The dividend yield of Regeneron Pharmaceuticals Inc is 0.4% (payout 9.1%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Regeneron Pharmaceuticals Inc (REGN)?
The net margin of Regeneron Pharmaceuticals Inc is 27.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Regeneron Pharmaceuticals Inc (REGN)?
The return on equity (ROE) of Regeneron Pharmaceuticals Inc is 14.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Regeneron Pharmaceuticals Inc (REGN)?
On an EBIT basis the return on assets of Regeneron Pharmaceuticals Inc is 17.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Regeneron Pharmaceuticals Inc (REGN)?
The operating margin of Regeneron Pharmaceuticals Inc is 33.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Regeneron Pharmaceuticals Inc (REGN)?
Revenue at Regeneron Pharmaceuticals Inc is growing +16.7% versus a year earlier (3y avg +5.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Regeneron Pharmaceuticals Inc (REGN)?
Earnings per share at Regeneron Pharmaceuticals Inc are growing −4.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Regeneron Pharmaceuticals Inc (REGN) hold?
Regeneron Pharmaceuticals Inc holds more cash than debt, $412M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Regeneron Pharmaceuticals Inc in the live analysis
One click puts Regeneron Pharmaceuticals Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 5, 2026